Loading...
NPI 1629579826 · Plymouth Meeting, PA · Clinical Medical Laboratory
Customize your policy alerts
Get alerted when relevant policies change without checking for updates manually.
Monitor payer policy activity
Religen is a clinical medical laboratory provider located in Plymouth Meeting, Pennsylvania. This profile covers 4 Medicare and 7 Medicaid CPT/HCPCS procedure codes, with claims volume, average reimbursement, and total revenue by code, benchmarked against other providers billing the same services.
Provider details (source: NPPES NPI Registry)
| Field | Value |
|---|---|
| Entity Type | Organization |
| Organization | Religen |
| Address | 5110 Campus Dr Ste 120 |
| City | Plymouth Meeting |
| State | PA |
| ZIP | 19462 |
| Taxonomy | Clinical Medical Laboratory |
| NPI Enumerated | February 22, 2018 |
Lifetime revenue by payer source (source: CMS Medicare & Medicaid claims data)
| Payer Source | Total Paid |
|---|---|
| Medicaid | $1.7M |
| Medicare | $349.2K |
Medicare revenue breakdown by CPT/HCPCS procedure code.
View: Bar Chart1 / 2
The CPT/HCPCS codes generating the most Medicare revenue for this provider.
4 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| 87631 | The lab analyst performs the technical steps to detect three to five types or subtypes of pathogens, such as adenovirus, influenza virus, coronavirus, metapneumovirus, parainfluenza virus,… | 1,330 | $140 | $185.5K |
| U0004 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by… | 1,540 | $70 | $114.1K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc,… | 1,060 | $30 | $26.4K |
| G2023 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | 1,080 | $20 | $24.8K |
How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 4 CPT/HCPCS codes.
Medicaid revenue breakdown by year and by CPT/HCPCS procedure code, including monthly billing trends and the top codes driving revenue.
View: By Year1 / 3
Every CPT/HCPCS code this provider has billed to Medicaid, with claims volume, average payment, and total revenue.
7 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| U0004 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by… | 45,090 | $30 | $1.1M |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc,… | 44,810 | $10 | $358.5K |
| G2023 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | 44,640 | $1 | $178.6K |
| 81412 | The lab analyst performs a genomic sequence analysis panel to evaluate the patient specimen for genetic sequences of at least nine genes that the code descriptor lists, relating to disorders… | 30 | $860 | $21.6K |
| 87635 | Using an amplified nucleic acid probe technique, the lab analyst performs the necessary steps to identify the nucleic acids from the severe acute respiratory syndrome coronavirus 2 (SARS–COV–2) virus… | 120 | $40 | $4.6K |
| 87631 | The lab analyst performs the technical steps to detect three to five types or subtypes of pathogens, such as adenovirus, influenza virus, coronavirus, metapneumovirus, parainfluenza virus,… | 1,490 | $0 | $0 |
| 99001 | The provider prepares a specimen collected from a patient at a location other than the provider’s office and sends it to an outside laboratory for analysis. | 120 | $0 | $0 |
How this provider's Medicaid billing volume and revenue compare to other Pennsylvania providers billing the same CPT/HCPCS codes.
Full comparison — all codes billed, vs. Pennsylvania median
7 rows
| CPT/HCPCS Code | Description | Rank | Provider Count | Median Claims | Avg Paid | Average Revenue |
|---|---|---|---|---|---|---|
| U0004 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by… | 3 | 70 | 620 | $60 | $464.8K |
| 87631 | The lab analyst performs the technical steps to detect three to five types or subtypes of pathogens, such as adenovirus, influenza virus, coronavirus, metapneumovirus, parainfluenza virus,… | 13 | 120 | 150 | $100 | $92.4K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc,… | 4 | 140 | 770 | $10 | $80.7K |
| 87635 | Using an amplified nucleic acid probe technique, the lab analyst performs the necessary steps to identify the nucleic acids from the severe acute respiratory syndrome coronavirus 2 (SARS–COV–2) virus… | 199 | 380 | 140 | $30 | $27.1K |
| 81412 | The lab analyst performs a genomic sequence analysis panel to evaluate the patient specimen for genetic sequences of at least nine genes that the code descriptor lists, relating to disorders… | 1 | 10 | 30 | $860 | $21.5K |
| G2023 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | 2 | 100 | 150 | $10 | $19.2K |
| 99001 | The provider prepares a specimen collected from a patient at a location other than the provider’s office and sends it to an outside laboratory for analysis. | 12 | 20 | 230 | $20 | $18K |
Other providers in the same ZIP code as Religen, ranked by combined Medicare and Medicaid revenue.
| Provider | State | Taxonomy | Medicare Revenue | Medicaid Revenue |
|---|---|---|---|---|
| Gemma Services | PA | Psychiatric Residential Treatment Facility | $0 | $23.8M |
| Access Services Inc | PA | Community/Behavioral Health Agency | $0 | $8.3M |
| Omesh Gupta | PA | Ophthalmology Physician | $7.1M | $80 |
| Mitchell Fineman | PA | Ophthalmology Physician | $7M | $0 |
| Michael Klufas | PA | Ophthalmology Physician | $7M | $0 |
| Richard Kaiser | PA | Ophthalmology Physician | $6.6M | $0 |
| Allen Chiang | PA | Ophthalmology Physician | $6.6M | $0 |
| Carl Regillo | PA | Ophthalmology Physician | $6.5M | $0 |
| Allen Ho | PA | Ophthalmology Physician | $6.4M | $0 |
| Yoshihiro Yonekawa | PA | Ophthalmology Physician | $6.4M | $0 |
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.